Over the past 12 months, 6 insiders at Allogene Therapeutics, Inc. filed 13 open-market SEC Form 4 transactions on ALLO: 0 purchases worth $0 and 13 sales worth $596K. Insiders have been net sellers over this period. The most recent filing was on Apr 21, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 21, 26 | Annie YoshiyamaSVP, Finance | SELL | 9.6K | $2.31 | $22K |
| Mar 16, 26 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | SELL | 4.8K | $2.47 | $12K |
| Mar 16, 26 | David D ChangPresident and CEO | SELL | 47.8K | $2.47 | $118K |
| Mar 2, 26 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | SELL | 7.1K | $2.60 | $19K |
| Feb 2, 26 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | SELL | 7.5K | $1.73 | $13K |
| Feb 2, 26 | David D ChangPresident and CEO | SELL | 95.3K | $1.80 | $171K |
| Feb 2, 26 | Earl Martin DouglasSVP, General Counsel | SELL | 22.9K | $1.76 | $40K |
| Feb 2, 26 | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | SELL | 24.0K | $1.76 | $42K |
| Feb 2, 26 | Zachary RobertsEVP of R&D | SELL | 35.7K | $1.77 | $63K |
| Feb 2, 26 | Annie YoshiyamaSVP, Finance | SELL | 4.2K | $1.72 | $7K |
| Jan 21, 26 | Zachary RobertsEVP of R&D | SELL | 26.3K | $1.56 | $41K |
| Nov 17, 25 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | SELL | 786 | $1.22 | $959 |
| Oct 21, 25 | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | SELL | 36.7K | $1.26 | $46K |
| Jun 10, 25 | Deborah M. MessemerDirector | SELL | 36.9K | $1.42 | $52K |
| Apr 21, 25 | Annie YoshiyamaSVP, Finance | SELL | 9.6K | $1.41 | $14K |
| Mar 14, 25 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | SELL | 5.5K | $1.98 | $11K |
| Mar 14, 25 | David D ChangPresident and CEO | SELL | 46.7K | $1.96 | $91K |
| Feb 18, 25 | Deborah M. MessemerDirector | SELL | 13.3K | $2.43 | $32K |
| Feb 3, 25 | David D ChangPresident and CEO | SELL | 46.0K | $1.68 | $77K |
| Feb 3, 25 | Earl Martin DouglasSVP, General Counsel | SELL | 6.4K | $1.71 | $11K |
| Feb 3, 25 | Timothy L. MooreChief Technical Officer | SELL | 14.7K | $1.71 | $25K |
| Feb 3, 25 | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | SELL | 4.4K | $1.73 | $8K |
| Feb 3, 25 | Zachary RobertsEVP of R&D | SELL | 18.8K | $1.70 | $32K |
| Jan 21, 25 | Zachary RobertsEVP of R&D | SELL | 27.2K | $1.78 | $48K |
| Dec 9, 24 | Deborah M. MessemerDirector | SELL | 9.1K | $2.18 | $20K |
| Dec 5, 24 | Franz B HumerDirector | SELL | 9.2K | $2.16 | $20K |
| Jun 18, 24 | Deborah M. MessemerDirector | SELL | 18.6K | $2.28 | $43K |
| May 30, 24 | Franz B HumerDirector | SELL | 11.2K | $2.34 | $26K |
| May 16, 24 | Arie BelldegrunDirector | BUY | 1.72M | $2.90 | $5.0M |
| Jan 30, 24 | Geoffrey M. ParkerCHIEF FINANCIAL OFFICER | BUY | 190 | $3.60 | $684 |
| Dec 18, 23 | Deborah M. MessemerDirector | SELL | 18.6K | $2.70 | $50K |
| Aug 7, 23 | Stephen MayoDirector | SELL | 10.0K | $4.29 | $43K |
| Feb 13, 23 | Veer BhavnagriGeneral Counsel | SELL | 3.0K | $6.85 | $21K |
| Jan 17, 23 | Veer BhavnagriGeneral Counsel | SELL | 3.0K | $7.04 | $21K |
| Dec 15, 22 | Veer BhavnagriGeneral Counsel | SELL | 5.6K | $7.53 | $42K |
| Aug 12, 22 | Owen N. WitteDirector | SELL | 5.0K | $17.25 | $86K |
| Aug 11, 22 | Owen N. WitteDirector | SELL | 10.0K | $16.50 | $165K |
| Aug 2, 22 | Rafael AmadoEVP of R&D and CMO | SELL | 2.0K | $11.97 | $24K |
| Jul 5, 22 | Rafael AmadoEVP of R&D and CMO | SELL | 2.0K | $11.44 | $23K |
| Jun 22, 22 | Owen N. WitteDirector | SELL | 10.0K | $11.76 | $118K |
| Jun 21, 22 | Rafael AmadoEVP of R&D and CMO | SELL | 2.0K | $11.18 | $22K |
| May 19, 22 | Rafael AmadoEVP of R&D and CMO | SELL | 11.5K | $7.40 | $85K |
| Mar 15, 22 | Rafael AmadoEVP of R&D and CMO | SELL | 5.2K | $7.71 | $40K |
| Mar 15, 22 | Veer BhavnagriGeneral Counsel | SELL | 8.8K | $7.68 | $68K |
| Mar 15, 22 | David D ChangPresident and CEO | SELL | 23.6K | $7.65 | $181K |
| Mar 15, 22 | Alison MooreChief Technical Officer | SELL | 8.7K | $7.63 | $66K |
| Mar 15, 22 | Eric Thomas SchmidtChief Financial Officer | SELL | 11.5K | $7.63 | $88K |
| Jan 12, 22 | Arie BelldegrunDirector | BUY | 155.0K | $12.60 | $2.0M |
| Jan 12, 22 | Joshua A KazamDirector | BUY | 15.0K | $12.60 | $189K |
| Oct 1, 21 | Rafael AmadoEVP of R&D and CMO | SELL | 11.5K | $24.35 | $280K |
Over the past 12 months, insiders at Allogene Therapeutics, Inc. filed 0 open-market purchases worth $0 and 13 sales worth $596K on ALLO, which makes them net sellers over the period. The most recent Form 4 was filed on Apr 21, 26.
The largest recent open-market ALLO insider purchase in our data was $5.0M by Arie Belldegrun, Director, filed on May 16, 24.
6 different insiders at Allogene Therapeutics, Inc. filed open-market SEC Form 4 transactions on ALLO over the last 12 months.
InsiderTape plots every ALLO insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Allogene Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →